Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Innate Pharma SA ( (FR:IPH) ) has issued an update.
Innate Pharma has announced the dosing of the first patient in a Phase 1 study of IPH4502, an innovative Antibody-Drug Conjugate (ADC), aimed at treating advanced solid tumors expressing Nectin-4. This study, initiated on January 27, 2025, marks a significant milestone for the company as it expands its clinical-stage pipeline with targeted ADCs, potentially providing new therapeutic options for patients with tumors resistant to existing treatments.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. It operates through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® platform, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). The company partners with major biopharmaceutical firms like Sanofi and AstraZeneca to advance cancer treatment innovations.
YTD Price Performance: -39.14%
Average Trading Volume: 616
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $149.8M
Learn more about IPH stock on TipRanks’ Stock Analysis page.
